Option chain shows key data for Silexion Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Silexion Therapeutics.

Silexion Therapeutics (NASDAQ:SLXN) Stock, Option Chain

Silexion Therapeutics

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Collaborating on Research

Biotech

News

Health Care

Movers

Trading Ideas

General

SLXN

Silexion&#39;s SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

Silexion Therapeutics&#39; Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Lattice Semiconductor

Pre-Market Outlook

Markets

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Movers_Stocks

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SWKS

Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics Corp

Press Releases

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Collaborates with Multi Billion Dollar Clinical Development Player, Advancing Revolutionary Cancer Treatment Toward Clinical Trials

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Maxim Group

Comments

Silexion Therapeutics

Silexion Therapeutics (SLXN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell